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S U M M A R Y
Background: The guidelines for initial empiric antimicrobial therapy for ventilator-associated pneumo-
nia (VAP) are highly dependent on the type of causative pathogen and the time of diagnosis. The
objective of this study was to examine the microbial causes of VAP and describe any variability by the
timing of VAP onset and over time.
Methods: A prospective surveillance study was conducted in the adult general intensive care unit of a
tertiary care hospital in Riyadh, Saudi Arabia. Microbial isolates obtained from blood and different
respiratory specimens of patients diagnosed with VAP (using the US Centers for Disease Control and
Prevention deﬁnition) between August 2003 and June 2009 were included.
Results: A total of 457 pathogens were identiﬁed during the study; 380 (83.2%) were associated with
primary VAP and 77 (16.8%) were associated with recurrent VAP. Of primary VAP pathogens, 159 (41.8%)
were associated with early-onset (<5 days) and 221 (58.2%) were associated with late-onset (5 days)
VAP. The most common pathogen identiﬁed was Acinetobacter spp (26.5%), followed by Pseudomonas
aeruginosa (21.7%), Staphylococcus aureus including methicillin-resistant S. aureus (MRSA) (15.3%),
Klebsiella spp (6.8%), Haemophilus spp (6.1%), and Enterobacter spp (5.0%). Acinetobacter spp and MRSA
were signiﬁcantly associated with late-onset VAP while Haemophilus spp and Streptococcus pneumoniae
were signiﬁcantly associated with early-onset VAP. Acinetobacter spp was the only pathogen associated
with recurrent VAP and its incidence showed a signiﬁcant increasing trend during the study period.
Acinetobacter spp was signiﬁcantly associated with prolonged ventilation, sedation, and nasogastric
intubation.
Conclusions: Acinetobacter baumannii is the most common and increasingly important pathogen
associated with VAP in our patients, especially late-onset and recurrent VAP.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Ventilator-associated pneumonia (VAP) continues to compli-
cate the course of 8–28% of patients receiving mechanical
ventilation and accounts for 15–25% of all types of intensive care
unit (ICU)-acquired infections.1–3 VAP can prolong hospital
stay by 2–10 extra days and consequently inﬂate inpatient* Corresponding author. Tel.: +966 1 2520088–43720/13250;
fax: +966 1 2520772.
E-mail address: balkhyh@hotmail.com (H.H. Balkhy).
1201-9712/$36.00 – see front matter  2013 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2013.02.004healthcare costs.4,5 Even higher than other device-associated
healthcare-associated infections (HAI), VAP is a deadly HAI with
10–30% attributable mortality.4–6 VAP is caused by a variety of
pathogens that originate from the patient’s ﬂora or the
healthcare environment.7
Awareness of the common microbial causes of VAP and
conﬁrmation of the speciﬁc cause at the individual level are
considered the single most important piece of information to guide
optimal antibiotic therapy.8 Moreover, guidelines for initial
empiric antimicrobial therapy for VAP are highly dependent on
the type of causative pathogen and its resistance pattern.9 This is
further complicated by the time of diagnosis (early- vs. late-onsetses. Published by Elsevier Ltd. All rights reserved.
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Early-onset VAP is frequently caused by aspiration of oropharyn-
geal secretions more likely to have community-type pathogens.10
Late-onset VAP (5 days or more) is more likely to be caused by
multidrug-resistant (MDR) pathogens, and is associated with
increased patient mortality and morbidity.9
The microbial causes of VAP vary considerably by geographic
location8 and over time.11 Studying geographic and temporal
changes is critical in determining the correct local empirical
antibiotic. Unfortunately data on microbial causes of VAP in Saudi
Arabia are limited, outdated, or based on a small number of
events.12–14 Moreover, none of the previous local studies has
explored the association between VAP onset and its causative
pathogens or monitored changes over time. The objective of the
current study was to examine the microbial causes of VAP among
adult ICU patients and to describe any variability by the timing of
VAP onset and over time.
2. Methods
2.1. Setting
The current study was conducted in an adult general ICU of a
tertiary care hospital, King Abdulaziz Medical City (KAMC) in
Riyadh, Saudi Arabia. KAMC is an approximately 900-bed tertiary
care facility that provides healthcare services to about 600 000
Saudi National Guard soldiers, employees, and their families. The
care provided ranges from primary and preventive care to tertiary
care. The adult ICU at KAMC is a 21-bed closed medical–surgical–
trauma unit covered by onsite board-certiﬁed intensivists 24 h per
day, 7 days a week,15 and admits approximately 900 patients per
year. The nurse-to-patient ratio is 1:1.
2.2. VAP surveillance
The details of VAP surveillance have been described
elsewhere.16 Brieﬂy, a prospective surveillance program was
established in 2003 as a joint project between the Intensive Care
Department and Infection Prevention and Control Department to
provide regular reports on the VAP rate and microbiology to
guide quality improvement projects. The same VAP deﬁnition
was used throughout the study period,17 and was based on that
of the US Centers for Disease Control and Prevention (CDC).18
Accordingly, VAP was deﬁned as a pneumonia occurring more
than 48 h after endotracheal intubation, with the following
diagnostic criteria: new or progressive inﬁltrates, consolidation,
or cavitation on chest X-ray, with one of the following: (a) new
onset purulent bronchial secretions with leukopenia (white
blood cells <4  109/l) or leukocytosis (12  109/l), or core
temperature 38.5 or 36 8C without other cause, (b) signiﬁcant
positive culture from blood, or (c) endotracheal aspirate
bronchoalveolar lavage (BAL), or culture from another relevant
site of infection. The diagnostic workup for VAP was mostly
done by obtaining endotracheal aspirates, which were processed
non-quantitatively. Diagnostic bronchoscopy was rarely utilized
and was mainly performed for patients with an immunocom-
promised status, unclear etiology of lung inﬁltrates, or non-
resolving pneumonia. Both primary (ﬁrst) and recurrent (second
or third) episodes of VAP during the same hospitalization were
included in the analysis. Recurrent VAP was diagnosed using the
same criteria as primary VAP only after an evidence of clearance
of the previous VAP.19 Primary VAP events were further
categorized as early-onset VAP (within the ﬁrst 4 days of
endotracheal intubation) or late-onset VAP (on the ﬁfth and
subsequent days following endotracheal intubation).202.3. Ventilator and patient care
Specialized respiratory therapists provided routine ventilator
care21 that involved closed endotracheal suctioning with the
system changed every 72 h or as clinically indicated, changing
ventilator circuits between patients or when they became soiled or
damaged, and changing the heat and moisture exchangers every 7
days or when visibly soiled. Oral decontamination using 0.2%
chlorhexidine was performed by nurses at least 4 times per day.
Disinfection of surfaces and equipment was performed by bedside
nurses or patient care technicians on a daily basis or as needed, as
per a standard protocol. Disinfection sprays and wipes containing
alcohol, chlorhexidine, and/or ammonium chloride were used.
2.4. Microbiological examination
Microbial isolates obtained from blood and different respira-
tory specimens from patients diagnosed with VAP between
August 1, 2003 and June 30, 2009 were included in the current
analysis. Specimens examined included blood, endotracheal
aspirate, BAL, and pleural ﬂuid. Endotracheal aspirates were sent
for nonquantitative cultures before starting empirical antimicro-
bial therapy. BAL was processed in a quantitative manner with a
cutoff of 104 colony-forming units/ml. Up to two isolates were
allowed per episode. Only the ﬁrst positive culture was included.
Multiple cultures with the same results from one episode of VAP
were re-coded just once. Culture results reported as ‘no growth’ or
‘normal ﬂora’ were categorized as ‘no pathogen identiﬁed’. Gram-
positive and Gram-negative bacteria were identiﬁed to the
species level using MicroScan Walkaway (Siemens, Frimley,
Camberley, UK), a conventional automated biochemical identiﬁ-
cation system.
2.5. Data analysis
Signiﬁcant differences in the frequency of a certain pathogen
between early- and late-onset VAP, as well as between primary and
recurrent VAP, were evaluated using the Chi-square test or Fisher’s
exact test, as appropriate. Similarly differences in the frequency of
a certain pathogen of VAP between KAMC and those reported by
the US National Healthcare Safety Network (NHSN)22 were
evaluated using the Chi-square test or Fisher’s exact test, as
appropriate. The prevalence trends of selected common pathogens,
as well as those that showed signiﬁcant differences between early-
and late-onset VAP, or primary and recurrent VAP, were plotted
over time. Signiﬁcant increasing or decreasing prevalence trends
over time were assessed using Mantel–Haenszel Chi square for
linear trend. Signiﬁcant trend differences between early- and late-
onset VAP, or primary and recurrent VAP, were assessed using
Mantel–Haenszel Chi square after stratiﬁcation by year. All p-
values were two-tailed. A p-value of <0.05 was considered
signiﬁcant. SPSS (release 17.0, SPSS Inc., Chicago, IL, USA), OpenEpi
(version 2.2), and PEPI-for-Windows software23 were used for all
statistical analyses.
3. Results
During the period between August 1, 2003 and June 30, 2009, a
total of 470 VAP events were diagnosed. Of these, 433 (92.1%) were
primary events and 37 (7.9%) were recurrent events. About 39.0% of
the primary VAP events were early-onset, while 61.0% were late-
onset. About a third (33.3%) of the VAP events were diagnosed mainly
based on clinical signs and symptoms with no pathogen identiﬁed.
About two-thirds of diagnosed VAP events had at least one pathogen
identiﬁed (46.7% single pathogen and 20.1% polymicrobial). A total of
457 pathogens were identiﬁed during the study; 380 (83.2%) were
Table 1
Distribution of pathogens isolated from ventilator-associated pneumonia (VAP) by recurrence status among study patients
Primary VAP
(n = 380)
Recurrent VAP
(n = 77)
Overall
(n = 457)
p-Value
Gram-positive 85 (22.4%) 12 (15.6%) 97 (21.2%) NS
Staphylococcus aureus 62 (16.3%) 8 (10.4%) 70 (15.3%) NS
MRSA 31 (8.2%) 6 (7.8%) 37 (8.1%) NS
Streptococcus pneumoniae 9 (2.4%) 2 (2.6%) 11 (2.4%) NS
Other Gram-positive pathogens 14 (3.7%) 2 (2.6%) 16 (3.5%) NS
Gram-negative 280 (73.7%) 62 (80.5%) 342 (74.8%) NS
Non-fermenter
Acinetobacter spp 91 (23.9%) 30 (39.0%) 121 (26.5%) 0.006
Pseudomonas aeruginosa 85 (22.4%) 14 (18.2%) 99 (21.7%) NS
Stenotrophomonas maltophilia 13 (3.4%) 2 (2.6%) 15 (3.3%) NS
Enterobacteriaceae
Klebsiella spp 27 (7.1%) 4 (5.2%) 31 (6.8%) NS
Enterobacter spp 19 (5.0%) 4 (5.2%) 23 (5.0%) NS
Escherichia coli 9 (2.4%) 3 (3.9%) 12 (2.6%) NS
Serratia spp 3 (0.8%) 2 (2.6%) 5 (1.1%) NS
Proteus spp 2 (0.5%) 0 (0.0%) 2 (0.4%) NS
Haemophilus spp 25 (6.6%) 3 (3.9%) 28 (6.1%) NS
Other Gram-negative pathogens 6 (1.6%) 0 (0.0%) 6 (1.3%) NS
Fungi 9 (2.4%) 1 (1.3%) 10 (2.2%) NS
Others 1 (0.3%) 1 (1.3%) 2 (0.4%) NS
Missing 5 (1.3%) 1 (1.3%) 6 (1.3%) NS
MRSA, methicillin-resistant Staphylococcus aureus.
A. El-Saed et al. / International Journal of Infectious Diseases 17 (2013) e696–e701e698associated with primary VAP and 77 (16.8%) were associated with
recurrent VAP (Table 1). Of primary VAP events, 159 (41.8%) were
associated with early-onset VAP and 221 (58.2%) were associated
with late-onset VAP (Table 2). The majority of isolates were obtained
from tracheal aspirates (87.1%), followed by blood (11.8%), BAL
(0.9%), and pleural ﬂuid (0.3%).
The majority (74.8%) of pathogens associated with VAP were
Gram-negative, while Gram-positives represented only 21.2%
(Table 1). The most common pathogen associated with VAP was
Acinetobacter spp (26.5%), followed by Pseudomonas aeruginosa
(21.7%), Staphylococcus aureus including methicillin-resistant S.
aureus (MRSA) (15.3%), Klebsiella spp (6.8%), Haemophilus spp
(6.1%), and Enterobacter spp (5.0%). Gram-negative pathogens
were slightly more encountered in recurrent VAP (80.5%) than in
primary VAP (73.7%), but the difference was not statistically
signiﬁcant (p = 0.182) (Table 1). Acinetobacter spp was the onlyTable 2
Distribution of pathogens isolated from primary ventilator-associated pneumonia (VAP
Early VAP
(n = 159)
Gram-positive 43 (27.0%) 
Staphylococcus aureus 31 (19.5%) 
MRSA 9 (5.7%) 
Streptococcus pneumoniae 7 (4.4%) 
Other Gram-positive pathogens 5 (3.1%) 
Gram-negative 110 (69.2%) 
Non-fermenter
Acinetobacter spp 23 (14.5%) 
Pseudomonas aeruginosa 30 (18.9%) 
Stenotrophomonas maltophilia 4 (2.5%) 
Enterobacteriaceae
Klebsiella spp 14 (8.8%) 
Enterobacter spp 9 (5.7%) 
Escherichia coli 2 (1.3%) 
Serratia spp 2 (1.3%) 
Proteus spp 1 (0.6%) 
Haemophilus spp 22 (13.8%) 
Other Gram-negative pathogens 3 (1.9%) 
Fungi 3 (1.9%) 
Others 0 (0.0%) 
Missing 3 (1.9%) 
MRSA, methicillin-resistant Staphylococcus aureus.
a Fisher exact test, otherwise Chi-square test.pathogen signiﬁcantly associated with recurrent VAP compared
to primary VAP (39.0% vs. 23.9%, p = 0.006). Gram-negative
pathogens were more encountered with late-onset VAP (76.9%)
than early-onset VAP (69.2%) and the difference was statistically
signiﬁcant (p < 0.001) (Table 2). Acinetobacter spp (30.8% vs.
14.5%, p < 0.001) and MRSA (10.0% vs. 5.7%, p = 0.023) were
signiﬁcantly associated with late-onset VAP. On the other hand,
Haemophilus spp (13.8% vs. 1.4%, p < 0.001) and Streptococcus
pneumoniae (4.4% vs. 0.9%, p = 0.015) were signiﬁcantly associ-
ated with early-onset VAP. Compared to patients with primary
VAP associated with other pathogens, patients with primary VAP
associated with Acinetobacter were more likely to have sedation
(p = 0.031), nasogastric intubation (p = 0.028), and prolonged
ventilation (p = 0.001); although it did not reach statistical
signiﬁcance (p = 0.094), they were also more likely to have
immunocompromising conditions (Table 3).) by the time of diagnosis among study patients
Late VAP
(n = 221)
Overall
(n = 380)
p-Value
42 (19.0%) 85 (22.4%) NS
31 (14.0%) 62 (16.3%) NS
22 (10.0%) 31 (8.2%) 0.023
2 (0.9%) 9 (2.4%) 0.015a
9 (4.1%) 14 (3.7%) NS
170 (76.9%) 280 (73.7%) <0.001
68 (30.8%) 91 (23.9%) <0.001
55 (24.9%) 85 (22.4%) NS
9 (4.1%) 13 (3.4%) NS
13 (5.9%) 27 (7.1%) NS
10 (4.5%) 19 (5.0%) NS
7 (3.2%) 9 (2.4%) NS
1 (0.5%) 3 (0.8%) NS
1 (0.5%) 2 (0.5%) NS
3 (1.4%) 25 (6.6%) <0.001
3 (1.4%) 6 (1.6%) NS
6 (2.7%) 9 (2.4%) NS
1 (0.5%) 1 (0.3%) NS
2 (0.9%) 5 (1.3%) NS
Table 3
Comparison of demographic and clinical characteristics of patients with primary ventilator-associated pneumonia by type of pathogen
Acinetobacter Other pathogens Total p-Value
Age, years
Mean  SD 49.0  21.0 47.6  21.2 48.0  21.1 0.600
18–39 38 (41.8%) 82 (41.6%) 120 (41.7%) 0.892
40–59 16 (17.6%) 39 (19.8%) 55 (19.1%)
60 37 (40.7%) 76 (38.6%) 113 (39.2%)
Gender
Male 63 (69.2%) 149 (75.6%) 212 (73.6%) 0.252
Female 28 (30.8%) 48 (24.4%) 76 (26.4%)
Admission category
Medical 48 (52.7%) 95 (48.2%) 143 (49.7%) 0.247
Surgical 13 (14.3%) 19 (9.6%) 32 (11.1%)
Trauma 30 (33.0%) 83 (42.1%) 113 (39.2%)
Scores
APACHE II 25.2  9.0 23.3  8.5 23.9  8.7 0.125
ISS 24.9  12.4 28.5  12.3 27.5  12.4 0.149
SAPS 44.0  21.2 47.9  14.4 47.3  14.6 0.743
Chronic diseases
Liver disease 11 (12.1%) 17 (8.6%) 28 (9.7%) 0.357
Cardiovascular diseases 18 (19.8%) 28 (14.2%) 46 (16.0%) 0.231
Respiratory diseases 19 (20.9%) 32 (16.2%) 51 (17.7%) 0.338
Renal diseases 13 (14.3%) 27 (13.7%) 40 (13.9%) 0.895
Immunocompromising conditiona 12 (13.2%) 14 (7.1%) 26 (9.0%) 0.094
Interventional factors
Sedation 36 (39.6%) 53 (26.9%) 89 (30.9%) 0.031
Nasogastric intubation 70 (76.9%) 126 (64.0%) 196 (68.1%) 0.028
Prolonged antibiotic therapy 10 (11.0%) 27 (13.7%) 37 (12.8%) 0.522
Ventilator days
Mean  SD 23.3  16.7 19.6  21.5 20.7  20.1 0.141
median (15) 33 (36.3%) 113 (57.4%) 146 (50.7%) 0.001
>median (>15) 58 (63.7%) 84 (42.6%) 142 (49.3%)
ICU length of stay (days) 26.2  17.4 22.6  23.0 23.7  21.4 0.177
SD, standard deviation; APACHE, Acute Physiology and Chronic Health Evaluation; ISS; Injury Severity Score; SAPS, Simpliﬁed Acute Physiology Score.
a Immunocompromising conditions were deﬁned as per APACHE II as follows: use of immunosuppressive agents or high-dose steroids (e.g., methylprednisolone 15 mg/
kg/day for 5 days), active chemotherapy or radiotherapy within 1 year, Hodgkin and non-Hodgkin lymphoma requiring chemotherapy or radiotherapy, leukemia,
lymphoma, diffuse metastatic cancer, or AIDS.
A. El-Saed et al. / International Journal of Infectious Diseases 17 (2013) e696–e701 e699Comparing the VAP-associated pathogens of the current study
to those of the NHSN (Table 4), KAMC had more VAP-associated
Acinetobacter spp (26.5% vs. 8.4%, p < 0.001) and P. aeruginosa
(21.7% vs. 16.3%, p = 0.003), but less S. aureus (15.3% vs. 24.4%,
p < 0.001), Klebsiella spp (6.8% vs. 9.6%, p = 0.045), Enterobacter spp
(5.0% vs. 8.4%, p = 0.012), and Enterococcus spp (0.2% vs. 1.3%,
p = 0.044) compared to NHSN hospitals.
The trends in selected VAP-associated pathogens over the years
were examined after excluding partial-year data. Despite the
decrease in the number of VAP-associated pathogens (and VAP
rate) over time, Gram-negative pathogens that represented aboutTable 4
Comparison of selected pathogens isolated from ventilator-associated pneumonia
(VAP) among study patients and the US National Healthcare Safety Network
(NHSN)a
KAMC
(2003–2009)
n = 462
NHSN
(2006–2007)
n = 5960
p-Value
Gram-positive 97 (21.2%)
Staphylococcus aureus 70 (15.3%) 1456 (24.4%) <0.001
Coagulase-negative staphylococci 9 (2.0%) 79 (1.3%) 0.254
Enterococcus spp 1 (0.2%) 77 (1.3%) 0.044
Gram-negative 342 (74.8%)
Acinetobacter spp 121 (26.5%) 498 (8.4%) <0.001
Pseudomonas aeruginosa 99 (21.7%) 972 (16.3%) 0.003
Klebsiella spp 31 (6.8%) 574 (9.6%) 0.045
Enterobacter spp 23 (5.0%) 498 (8.4%) 0.012
Escherichia coli 12 (2.6%) 271 (4.6%) 0.054
Fungi 10 (2.2%) 160 (2.7%) 0.524
KAMC, King Abdulaziz Medical City.
a Pathogens with no available comparable data from NHSN were not included in
the table. NHSN data were derived from different types of ICUs and non-ICU
locations in 463 hospitals in the USA.76% of all isolates during the study, were relatively constant over
time (p for trend 0.147). Acinetobacter spp was the only Gram-
negative pathogen to show a signiﬁcant increasing trend during
the studied period (p for trend 0.033). P. aeruginosa had wide yearly
variation but no signiﬁcant trend (p for trend 0.363). Klebsiella spp
and MRSA were relatively constant over time (p for trend 0.110 and
0.976, respectively). The incidence trends of Acinetobacter-
associated primary and recurrent VAP during the studied period
were different (Mantel–Haenszel p = 0.011), with a generally
increasing trend observed in recurrent VAP (p for trend 0.066) but
not in primary VAP (p for trend 0.140). Acinetobacter spp was more
commonly associated with late-onset VAP throughout the study
duration (Mantel–Haenszel p = 0.001).
4. Discussion
This study reports the bacterial causes of VAP among patients of
a general adult ICU over a period of 6 years. Acinetobacter spp was
the most common VAP pathogen (26.5%) in the current study,
followed by P. aeruginosa (21.7%) and S. aureus (15.3%). The three
pathogens together accounted for almost two-thirds of all VAP
pathogens. The current ﬁndings are different from those reported
from Western and several developing countries. In a review of 22
VAP studies between 1996 and 2007 from developing countries, P.
aeruginosa was the most common isolated pathogen (20–52%) in
14 studies, while Acinetobacter spp was the most common isolated
pathogen (21–36%) in only six studies.13 Data from 55 ICUs
between 2002 and 2005 in eight developing countries showed that
P. aeruginosa and Enterobacteriaceae were the most common
isolated pathogens (26% each), followed by Acinetobacter spp
(20%).24 On the other hand, reports from the USA and Europe
showed that S. aureus (23–32%) and P. aeruginosa (16–22%) were
A. El-Saed et al. / International Journal of Infectious Diseases 17 (2013) e696–e701e700the leading causes of VAP, while Acinetobacter spp was responsible
for only 4–8% of VAP events.7,22,25
Several factors may explain the high and increasing contribu-
tion of Acinetobacter spp to VAP. First, our VAP patients were
exposed to more prolonged ventilation times (average 20.7 days)
than Western patients (average 14.3)26 and were more likely to
have late-onset VAP than reported in Western patients (61% vs.
44–49%).27,28 Similar to previous studies, Acinetobacter in the
current study was associated with prolonged ventilation and late-
onset VAP.8 Second, the studied ICU experienced an outbreak of
Acinetobacter in 2007. Acinetobacter spp is particularly known as
an important cause of VAP outbreaks in ICUs from hidden sources
of colonized patients and contaminated surfaces.29,30 Third,
nasogastric intubation (which was signiﬁcantly associated with
Acinetobacter) was extensively used (68.1%) in our patients.
Nasogastric intubation is believed to increase the risk of VAP by
increasing the risk of sinusitis.9 Lastly, although the studied ICU
implemented a standard disinfection protocol for surfaces and
equipment, it may be insufﬁcient to control Acinetobacter, which is
particularly known for its resistance to disinfectants and long
survival on dry surfaces.30,31
Only a few studies have evaluated VAP recurrence.32 Moreover
there has been confusion between the concepts of ‘recurrence’,
which usually indicates prevention failure, and ‘persistence’,
which usually indicates treatment failure.19 The rate of VAP
recurrence in the current study (16.8%) was less than reported in a
recent meta-analysis (26.8%).32 This may be partially explained by
the different deﬁnitions used. In our patients, recurrent VAP was
diagnosed at an average of 17.6  12.0 days after the previous VAP
and only after evidence of clearance of the previous VAP. Acinetobacter
spp was the only pathogen signiﬁcantly associated with recurrent
VAP in our patients. Supporting this ﬁnding, a recent report showed
that a high rate of VAP relapse was associated with primary infection
by Acinetobacter spp.33
The difference in VAP pathogens between early- and late-onset
VAP observed in the current study was identical to reports from
elsewhere.8,9,34 Several studies have shown S. pneumoniae and
Haemophilus inﬂuenzae to be the predominant respiratory patho-
gens within the ﬁrst week of intubation, and that they are
subsequently replaced by multi-resistant ﬂora, such as MRSA, P.
aeruginosa or Acinetobacter baumanii.8,9,34 This ﬁnding should have
a great impact on the choice of empirical antibiotics for VAP.9 Since
the latter group of pathogens are probably more resistant and
represented more than 55% of VAP pathogens in our patients,
reducing the duration of ventilation (for example by accelerated
weaning) may positively impact VAP treatment.
About a third of the VAP events in the current study had
negative cultures. It has been shown that bacteriologic conﬁrma-
tion of clinically suspected VAP ranges between 22% and 55%.35 In
addition, patients might have been on antimicrobial therapy at the
time that endotracheal cultures were taken.
The current study had several strengths and some limitations.
The study is by far the largest epidemiologic surveillance study on
ICU patients in Saudi Arabia. The data were collected prospectively
and the CDC-based VAP deﬁnition used was constant during the
entire study period. However, the current NHSN deﬁnition no longer
allows the clinical deﬁnition. The large number of isolates included
(>450) allowed us to examine the bacterial causes by time of VAP
onset, by recurrence, across the years, and for less common
pathogens. Since the local data is limited, the ﬁndings may help
local physicians to choose the correct empirical antibiotic. However,
being a single-center study may limit the generalizability of the
ﬁndings. Another weakness of the study is that the majority (87.1%)
of isolates were cultured in a non-quantitative manner from
endotracheal aspirates. This may have limited the speciﬁcity of
culture results with more false-positive results.In conclusion, Gram-negative pathogens are responsible for
about three quarters of VAP in our patients. Acinetobacter
baumannii is the most common and increasingly important
pathogen associated with VAP, especially late-onset and recurrent
VAP. Our ICU should continue to actively screen for Acinetobacter
in all admitted patients, shorten the duration of ventilation,
minimize sedation, encourage oral gastric rather than nasogastric
intubation, and improve currently implemented infection control
measures, including environmental disinfection.
Ethical approval: The required approvals were obtained for this
work in accordance with KAMC regulations.
Conﬂict of interest: Nothing to disclose.
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